57982-78-2 | Budipine

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$127.00	$89.00
25mg	95%	in stock	$322.00	$226.00
500mg	98% by HPLC	in stock	$5,188.00	$3,631.00
1000mg	98% by HPLC	in stock	$8,267.00	$5,787.00

Description

• Catalog Number: AB52997
• Chemical Name: Budipine
• CAS Number: 57982-78-2
• Molecular Formula: C21H27N
• Molecular Weight: 293.4458
• MDL Number: MFCD00866585
• SMILES: CC(N1CCC(CC1)(c1ccccc1)c1ccccc1)(C)C

Computed Properties

• Complexity: 313
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 5.2

Literature

• Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).

  Movement disorders : official journal of the Movement Disorder Society 20110101

• [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].

  Fortschritte der Neurologie-Psychiatrie 20100301

• A new strategy for antidepressant prescription.

  Frontiers in neuroscience 20100101

• Paradoxical aspects of parkinsonian tremor.

  Movement disorders : official journal of the Movement Disorder Society 20080130

• Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats.

  Brain research 20061030

• Budipine in Parkinson's tremor.

  Journal of the neurological sciences 20061025

• [Diagnosis and therapy of idiopathic Parkinson's disease].

  MMW Fortschritte der Medizin 20060515

• Efficacy and safety of high-dose cabergoline in Parkinson's disease.

  Acta neurologica Scandinavica 20060101

• Efficacy of budipine and placebo in untreated patients with Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20050801

• Pharmacotherapy of Parkinson's disease in Germany.

  Journal of neurology 20050801

• Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats.

  British journal of pharmacology 20050701

• The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice.

  Neuroscience letters 20050701

• Synergism between topiramate and budipine in refractory status epilepticus in the rat.

  Epilepsia 20041101

• Antiapoptotic effects of budipine.

  Journal of neural transmission (Vienna, Austria : 1996) 20041001

• Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.

  Naunyn-Schmiedeberg's archives of pharmacology 20031101

• Evaluation of possible pro- or antioxidative properties and of the interaction capacity with the microsomal cytochrome P450 system of different NMDA-receptor ligands and of taurine in vitro.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20030601

• [Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].

  MMW Fortschritte der Medizin 20030526

• [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].

  MMW Fortschritte der Medizin 20020506

• Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.

  Archives of neurology 20020501

• Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.

  Current drug targets 20010901

• Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.

  Pharmacogenetics 20010801

• Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.

  International journal of clinical pharmacology and therapeutics 20010601

• Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings.

  Movement disorders : official journal of the Movement Disorder Society 20010501

• Non-dopaminergic drug treatment of Parkinson's disease.

  Expert opinion on pharmacotherapy 20010401

• [Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine].

  Fortschritte der Neurologie-Psychiatrie 20010201

• Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease.

  Journal of neurology 20000901

• Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.

  European psychiatry : the journal of the Association of European Psychiatrists 19991001

• [Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines].

  Arzneimittel-Forschung 19840101